HEMOGENYX PLC (LON:HEMO) SECTOR – HEALTHCARE RATING – CORP* MARKET CAP – £10.9m CURRENT PRICE – 2.9p# ANALYSTS: LIAM GASCOIGNE-COHEN |
|
Year-end Dec |
2016A |
2017A |
2018E |
2019E |
2020E |
|
Revenue (£m) |
- |
- |
No forecasts provided |
|||
EBITDA (£m) |
(0.5) |
(2.3) |
|||||
Pre-tax profit (£m) |
(0.5) |
(2.4) |
|||||
EPS (p) |
(0.00) |
(0.01) |
|||||
DPS (p) |
- |
- |
|||||
Net Cash/(Debt) (£m) |
(0.2) |
1.9 |
|||||
P/E (x) |
- |
- |
|||||
Dividend yield (%) |
- |
- |
|||||
EV/EBITDA (x) |
- |
- |
|||||
|
SOURCE: Northland Capital Partners Limited estimates. #Priced at prior trading day close. *Northland Capital Partners Limited provides acts as Joint Broker to Hemogenyx plc and therefore this information should be viewed as a Marketing Communication. |
Initiation of research: Disrupting current blood disease therapy (Note attached) |
NORTHLAND VIEW |
Hemogenyx is a biotechnology company quoted on the LSE Standard List. The Company is developing novel therapies for blood diseases which aim to offer a safer and more accessible patient pathway than current practice. Although the products are at the preclinical stage, the Company is already generating revenue through multiple collaborations with biopharmaceutical companies.
Although the Company has demonstrated strong progress across its pipeline, the share price remains below its IPO price of 3.5p/share. With multiple collaboration agreements and investment from industry we view the Company as undervalued. |
COMPANY DESCRIPTION Preclinical stage biotechnology company focused on the development of novel therapies for blood diseases. |